Innovus Pharma's (OTCQB: INNV) supplement RecalMax has aced clinical trials and could prove its worth in an US$11bn neurodegenerative market.
RecalMax was tested in a four-month human clinical trial on 72 patients with low memory and learning.
After taking one capsule twice a day for 16 weeks, patients reported a 115% increase in the recall of words and names, a 49.5% increase in maintaining thoughts when distracted, and a 35% increase in processing speed.
The supplement was also well-tolerated with no serious adverse events reported.
Parkinson's disease and Alzheimer's disease are the two most prevalent medical conditions falling into the neurodegenerative market.
The market is estimated at around US$11bn annually.
Both are characterized by neurological problems affecting memory, learning, and nerve function, eventually leading to premature death.
Innovus Pharma estimates that the immediate market for RecalMax could be worth around US$3bn.
Management believes that it can capture enough of the market to generate about US$5mln in annual revenue by deploying the treatment across its well-established Beyond Human Platform and online marketing channels.